Skip to search formSkip to main contentSkip to account menu

ICRF 193

Known as: ICRF-193 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
NotePreparation Cells Using of Extended Metaphase Chromosomes from a Topoisomerase II Inhibitor , ICRF-193 JSBA Human Cu } tured
short-time expesure of this drug to human HL60 cells in a suspension culture before harvest resulted in obtaining more extended… 
2016
2016
Unique spindle phenotype induced by ICRF-193, an anticancer topoisomerase II inhibitor, in fission yeast
2001
2001
CANCER-ASSOCIATED CHROMOSOMAL ABERRATIONS
DNA topoisomerases catalyze topological changes in DNA that are essential for normal cell cycle progression and therefore they… 
2000
2000
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive…
F 11782 is a newly identified catalytic inhibitor of topoisomerases I and II, without any detectable interaction with DNA. This… 
1997
1997
Effects of ICRF-193, a catalytic inhibitor of DNA topoisomerase II, on sister chromatid exchange
To investigate whether mammalian DNA topoisomerase II is directly involved in recombination events, the effects of ICRF-193, a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)